Share-based Payment Arrangement, Expense of Lucid Diagnostics Inc. from 30 Sep 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Lucid Diagnostics Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2021 to 30 Sep 2025.
  • Lucid Diagnostics Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,152,000, a 6.2% decline year-over-year.
  • Lucid Diagnostics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $4,497,000, a 4% increase year-over-year.
  • Lucid Diagnostics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $4,534,000, a 34% decline from 2023.
  • Lucid Diagnostics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $6,822,000, a 54% decline from 2022.
  • Lucid Diagnostics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $14,991,000, a 56% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Lucid Diagnostics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $4,497,000 $1,152,000 -$76,000 -6.2% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $4,573,000 $1,143,000 -$58,000 -4.8% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $4,631,000 $1,030,000 +$97,000 +10% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $4,534,000 $1,172,000 +$209,000 +22% 01 Oct 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
Q3 2024 $4,325,000 $1,228,000 -$24,000 -1.9% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $4,349,000 $1,201,000 -$198,000 -14% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $4,547,000 $933,000 -$2,275,000 -71% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $6,822,000 $963,000 -$2,778,000 -74% 01 Oct 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q3 2023 $9,600,000 $1,252,000 -$2,319,000 -65% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $11,919,000 $1,399,000 -$2,445,000 -64% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $14,364,000 $3,208,000 -$627,000 -16% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $14,991,000 $3,741,000 01 Oct 2022 31 Dec 2022 10-K 25 Mar 2024 2023 FY
Q3 2022 $3,571,000 +$799,000 +29% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $3,844,000 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $3,835,000 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q3 2021 $2,772,000 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3

Lucid Diagnostics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $4,534,000 -$2,288,000 -34% 01 Jan 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
2023 $6,822,000 -$8,169,000 -54% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
2022 $14,991,000 +$5,392,000 +56% 01 Jan 2022 31 Dec 2022 10-K 25 Mar 2024 2023 FY
2021 $9,599,000 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.